NFKB1 and plasma cell myeloma: The clinically approved inhibitors of the b5 proteasomal protease are bortezomib, carfilzomib, and ixazomib, which have multifaceted antiproliferative effects, including inhibition of NF-κB signaling, and have shown the most clinical benefit in multiple myeloma [159].